← board
CMMB
distress 5/10 · elevated risk$1.46+2%today-69% from 52w high
Revenue
pre-revenue
Liquidity
$8M
Runway
0.3 yrs
Shares 1y
0%
Price & events
-14.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.1%
1D
-3.9%
1W
-2.7%
1M
-9.9%
3M
-13.1%
6M
-66.8%
1Y
-70.4%
2Y
-97.9%
5Y
-98.7%
All
Overview
- Market Cap
- $840.06M
- Volume
- 7.56K
- 52 Week Range
- $1.43 – $4.68
- Total Shares
- 575.38M
- Float Shares
- 6.40M
- Short %
- 2.04%
- % Held by Insiders
- 11.09%
- % Held by Institutions
- 4.76%
- RVOL
- 0.04x
- Beta
- 0.64
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $5 (+242% upside) · 1 analysts
- 2025-08-27OppenheimerOutperform
- 2025-05-16OppenheimerOutperform
- 2025-02-20Maxim GroupBuy
- 2024-11-15OppenheimerOutperform
Competitors
- none identified
Recent news
- 2026-06-28Enterprise value to revenue forward of Chemomab Therapeutics Ltd. – NASDAQ:CMMB - TradingView
- 2026-06-27Chemomab Therapeutics Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:CMMB) - TradingView
- 2026-06-17Chemomab Therapeutics Ltd (CMMB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
- 2026-06-17Chemomab Therapeutics Ltd - TradingKey
- 2026-06-02Chemomab Therapeutics (CMMB) reshapes board and audit committee leadership - Stock Titan
- 2026-06-01Chemomab (CMMB) CEO adds 9,804 ADS in May 29 purchases - Stock Titan
- 2026-05-27CMMB - Chemomab Therapeutics Ltd ADR Stock Price and Quote - Finviz
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.